There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > BUSINESS
BUSINESS
- Eisai Signs Agreement on Marketing Halaven in 8 Central and Eastern European Countries
April 6, 2012
- Toray Grants German Company Marketing Rights for Antipruritic Agent in Europe
April 6, 2012
- Takeda Considering Manufacturing Plant Move on Power Shortage: Keizai Doyukai Chairman Hasegawa
April 5, 2012
- Nihon Chouzai to Soon Conclude Memorandum with Wholesalers for Provisional Prices
April 5, 2012
- Pharmacists Expect Increase in Use of Amlodipine Generics: Survey
April 5, 2012
- GSK Applies for Fixed-Dose Combination Tablet for Treatment/Prevention of Malaria
April 5, 2012
- Shionogi Sees Positive Results of PIII Study for Anti-HIV Drug
April 5, 2012
- Ajinomoto Pharmaceuticals Obtains Rights to Develop, Commercialize CC Treatment in Japan, Asia
April 5, 2012
- Ajinomoto Pharmaceuticals Ties Up with DKSH Group in Vietnam
April 5, 2012
- Novartis Draws Up Guidelines for MRs on How to Cope in Times of Disaster
April 4, 2012
- Sogo Rinsho HD to Establish New Subsidiary for Full-Scale Market Entry of CRO Business
April 4, 2012
- Genzyme Changes Distributor of 3 Products Including Thymoglobulin to sanofi-aventis
April 4, 2012
- Abbott Receives Approval for Diagnostic Agent for Identification of Patients for Xalkori Administration
April 4, 2012
- Mochida Aims for Sales of Over 100 Billion Yen in FY2014: New Midterm Management Plan
April 4, 2012
- Top Leaders Stress Importance of Globalization in Addresses to Incoming New Graduates
April 4, 2012
- ALK Inhibitor Xalkori Approved, to Be Provided before NHI Listing: Pfizer Japan
April 3, 2012
- Eisai Licenses Bexarotene Rights to Minophagen in Emerging Countries
April 3, 2012
- Kowa Sets Up Kowa Generic for Generic Business
April 3, 2012
- Kyowa Kirin Applies for Novel Parkinson’s Disease Treatment KW-6002
April 3, 2012
- Shionogi Acquires Global Rights for OncoTheraphy’s Cancer Vaccines
April 2, 2012
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…